<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00361972</url>
  </required_header>
  <id_info>
    <org_study_id>15444</org_study_id>
    <secondary_id>IRB #15444</secondary_id>
    <nct_id>NCT00361972</nct_id>
  </id_info>
  <brief_title>Elucidation of Acid-Induced Pulmonary Inflammation</brief_title>
  <official_title>Elucidation of Acid-Induced Pulmonary Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate how heartburn may lead to different types of inflammation in one's&#xD;
      airways. Additionally, the study will determine whether aggressive treatment of heartburn&#xD;
      results in improvement in both symptoms of heartburn and asthma but also in documented&#xD;
      improvement in airway inflammation as determined by biopsy. The results of this study will be&#xD;
      important in directing future research into the relationship between heartburn and asthma and&#xD;
      may provide a clue whether certain subtypes of asthma may be caused primarily by&#xD;
      gastroesophageal reflux (GER).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, many Americans suffer from asthma. The exact mechanism by which airway&#xD;
      inflammation leads to asthma symptoms has yet to be clearly explained. In previous studies,&#xD;
      persons with asthma appear to have different types of inflammation in their lungs. The&#xD;
      reasons for this difference remain a mystery. Allergy is known to play a role in&#xD;
      bronchospasm. Other mechanisms have not been discovered.&#xD;
&#xD;
      It is known that asthma and heartburn are correlated. Studies have confirmed a direct&#xD;
      relationship between cough and heartburn (Gastroesophageal reflux). Other researchers have&#xD;
      determined that asthma is often worsened by GER. Determination of the exact relationship&#xD;
      between these two entities remains unclear.&#xD;
&#xD;
      Heartburn may contribute to airway inflammation in asthmatics, resulting in different&#xD;
      patterns of inflammation between those people with and without GER. In fact, adult-onset&#xD;
      asthma may result primarily from longstanding heartburn. This has yet to be proven.&#xD;
&#xD;
      This study will evaluate how heartburn may lead to different types of inflammation in one's&#xD;
      airways. Additionally, the goal of this study is to determine whether aggressive treatment of&#xD;
      heartburn results in improvement in both symptoms of heartburn and asthma but also in&#xD;
      documented improvement in airway inflammation as determined by biopsy. The results of this&#xD;
      study will be important in directing future research into the relationship between heartburn&#xD;
      and asthma and may provide a clue whether certain subtypes of asthma may be caused primarily&#xD;
      by GER.&#xD;
&#xD;
      A total of 30 subjects will be studied, randomized to twice daily lansoprazole or placebo.&#xD;
      Study procedures are as follows:&#xD;
&#xD;
      A. Esophageal studies and validated questionnaires:&#xD;
&#xD;
      Patients will be evaluated with validated SF-36 Quality of Life Questionnaire, Mini-asthma&#xD;
      Quality of Life Questionnaire, and GER Questionnaire. Patients will undergo esophageal&#xD;
      manometry and pH detection with a 24- hour pH probe to confirm the presence of pathologic&#xD;
      GER.&#xD;
&#xD;
      B. Bronchoscopy:&#xD;
&#xD;
      After an overnight fast, subjects will report to the bronchoscopy suite as directed.&#xD;
      Bronchoscopy with bronchoalveolar lavage (BAL) and bronchial biopsy will be performed&#xD;
      following the University of Utah's standardized protocol. Bronchoscopy and endobronchial&#xD;
      biopsies present minimal risk to asthmatic airways when performed by appropriate, trained&#xD;
      personnel. Conscious sedation with intravenous remifentanyl and propofol will be administered&#xD;
      by a trained nurse experienced in conscious sedation. The nose and pharynx will be&#xD;
      anesthetized with 1% lidocaine administered by nebulization and by lidocaine jelly&#xD;
      administered topically to the nasal mucosa. Additional lidocaine will be administered via the&#xD;
      bronchoscope to the vocal cords, trachea, main carina and mainstem bronchi. The total dose of&#xD;
      lidocaine will not exceed 400 mg. All subjects will have continuous cardiac and oxygen&#xD;
      saturation monitoring and will receive supplemental oxygen during the procedure sufficient to&#xD;
      maintain SpO2 &gt; 90%.&#xD;
&#xD;
      The subject will be placed in a recumbent position and the bronchoscope will be introduced&#xD;
      via the nose. After passing the vocal cords, the bronchoscope will be introduced via the&#xD;
      right mainstem bronchus into the right middle lobe where it will be wedged into a segmental&#xD;
      bronchus. (Should, for any reason, the right middle lobe be inaccessible, the same procedure&#xD;
      will be used to wedge the bronchoscope into a lingular segment in the left lung.) A 60 cc&#xD;
      aliquot of room temperature normal saline will be instilled through the bronchoscope and&#xD;
      recovered using the same syringe. This procedure will be repeated three more times (total&#xD;
      lavage volume of 240 cc) and the recovered volumes will be pooled and measured. Forceps&#xD;
      biopsies of respiratory mucosa will then be taken from the trachea, main carina, bronchus&#xD;
      intermedius and right middle lobe areas. Two to six biopsies will be taken from each site.&#xD;
      Specific tissue from each site will be frozen and stored for future use.&#xD;
&#xD;
      Individuals will be randomized to lansoprazole 30 mg twice daily or placebo (all patients&#xD;
      will undergo lifestyle modification for reflux) for 6 weeks. It has been determined in&#xD;
      previous studies that higher levels of acid suppression are needed to result in clinical&#xD;
      improvement in asthma.&#xD;
&#xD;
      Patients will be monitored by telephone at regular intervals. Rescue inhaler use,&#xD;
      hospitalizations, exercise tolerance, and study compliance will be assessed and recorded to&#xD;
      document clinical progress. Patients will be asked to maintain their standard inhaler therapy&#xD;
      (especially that of inhaled steroids). Any changes to the therapy will be immediately&#xD;
      reported to the investigators. If subjects experience an acute flare, appropriate medications&#xD;
      will be given until the patient is stable to return to their initial inhaler regimen. If&#xD;
      patients remain on stable medication throughout the trial, repeat bronchoscopy will be&#xD;
      performed at 6 weeks.&#xD;
&#xD;
      After 6 weeks, patients will once again undergo bronchoscopy with BAL/biopsies. Cytokine&#xD;
      protein arrays will be repeated. Comparisons will then be made intra-group before and after&#xD;
      therapy. Additional comparisons of inflammation and bronchial hyper-responsiveness will be&#xD;
      made between groups. Randomization will allow the investigators to control for any changes in&#xD;
      cytokine patterns due to seasonal affect (if both groups reduce the concentration of&#xD;
      Interleukin-5 in a similar pattern, this is more likely seasonal than due to acid&#xD;
      suppression).&#xD;
&#xD;
      Primary outcome will include change in cellular infiltration in the bronch specimens of&#xD;
      lymphocytes. Secondary outcome will include RNA expression changes of tumor necrosis factor&#xD;
      (TNF) alpha from BAL samples.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    limited recruitment&#xD;
  </why_stopped>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Lymphocyte Count</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Change in mean lymphocyte count in bronchus intermedius biopsies between lansoprazole and placebo groups, measured in lymphocytes per square millimeter. Overall mean differences were compared (post-intervention mean lymphocyte count minus pre-intervention mean lymphocyte count) between the two intervention groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Log Change in Tumor Necrosis Factor (TNF) Alpha Measurement</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Change in TNF alpha cytokine expression from bronchoalveolar lavage aspirate samples between lansoprazole and placebo groups, measured in log picograms per milliliter (log (pg/mL)) units, pre- and post-intervention.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Gastroesophageal Reflux</condition>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Lansoprazole therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lansoprazole 30 mg orally twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo orally twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lansoprazole</intervention_name>
    <description>30 mg of lansoprazole twice daily for 6 weeks</description>
    <arm_group_label>Lansoprazole therapy</arm_group_label>
    <other_name>Prevacid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo comparator to lansoprazole 30 mg, twice daily for 6 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. chronic cough consistent with bronchoreactivity&#xD;
&#xD;
          2. Gastroesophageal reflux&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe asthmatics who have been hospitalized within the last 6 months or who have&#xD;
             required oral steroid use within the last 4 weeks&#xD;
&#xD;
          2. Severe coronary artery disease&#xD;
&#xD;
          3. Cigarette/cigar smoking within the last 6 months&#xD;
&#xD;
          4. Documented allergies affecting the respiratory system&#xD;
&#xD;
          5. Subjects with contraindications to pH/impedance probe&#xD;
&#xD;
               1. Hemophilia&#xD;
&#xD;
               2. Septal deviation&#xD;
&#xD;
          6. Subjects with contraindications to bronchoscopy as outlined by the American Thoracic&#xD;
             Society Guidelines&#xD;
&#xD;
          7. Anticoagulation&#xD;
&#xD;
          8. Pregnancy&#xD;
&#xD;
          9. Incarcerated patients&#xD;
&#xD;
         10. Current oral steroid use (may suppress levels of inflammation)&#xD;
&#xD;
         11. Upper respiratory infection within the last 2 weeks&#xD;
&#xD;
         12. Ongoing acid suppression with a proton pump inhibitor, however, patients may be&#xD;
             included if they have discontinued their proton pump inhibitor within the last 1 month&#xD;
             with stable asthma symptoms as defined by stable utilization of inhaled steroids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathryn Peterson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah Health Sciences Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>August 8, 2006</study_first_submitted>
  <study_first_submitted_qc>August 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2006</study_first_posted>
  <results_first_submitted>January 14, 2016</results_first_submitted>
  <results_first_submitted_qc>June 25, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 5, 2016</results_first_posted>
  <last_update_submitted>June 25, 2016</last_update_submitted>
  <last_update_submitted_qc>June 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Kathryn A. Peterson</investigator_full_name>
    <investigator_title>md</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>in clinics over 18 month period</recruitment_details>
      <pre_assignment_details>washout after lansoprazole or placebo given</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lansoprazole</title>
          <description>lansoprazole : 30 mg of lansoprazole twice daily for 6 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo comparator to lansoprazole, 30 mg, twice a day for 6 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lansoprazole</title>
          <description>lansoprazole : 30 mg of lansoprazole twice daily for 6 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo comparator to lansoprazole 30 mg twice daily for 6 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" lower_limit="20" upper_limit="57"/>
                    <measurement group_id="B2" value="43" lower_limit="26" upper_limit="62"/>
                    <measurement group_id="B3" value="41" lower_limit="20" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Lymphocyte Count</title>
        <description>Change in mean lymphocyte count in bronchus intermedius biopsies between lansoprazole and placebo groups, measured in lymphocytes per square millimeter. Overall mean differences were compared (post-intervention mean lymphocyte count minus pre-intervention mean lymphocyte count) between the two intervention groups.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole</title>
            <description>lansoprazole: 30 mg lansoprazole twice daily for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo comparator to lansoprazole 30 mg, twice daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lymphocyte Count</title>
          <description>Change in mean lymphocyte count in bronchus intermedius biopsies between lansoprazole and placebo groups, measured in lymphocytes per square millimeter. Overall mean differences were compared (post-intervention mean lymphocyte count minus pre-intervention mean lymphocyte count) between the two intervention groups.</description>
          <units>Lymphocytes per square millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57" spread="10"/>
                    <measurement group_id="O2" value="-3" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Log Change in Tumor Necrosis Factor (TNF) Alpha Measurement</title>
        <description>Change in TNF alpha cytokine expression from bronchoalveolar lavage aspirate samples between lansoprazole and placebo groups, measured in log picograms per milliliter (log (pg/mL)) units, pre- and post-intervention.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole</title>
            <description>lansoprazole : 30 mg of lansoprazole twice daily for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo comparator to lansoprazole 30 mg, twice daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Log Change in Tumor Necrosis Factor (TNF) Alpha Measurement</title>
          <description>Change in TNF alpha cytokine expression from bronchoalveolar lavage aspirate samples between lansoprazole and placebo groups, measured in log picograms per milliliter (log (pg/mL)) units, pre- and post-intervention.</description>
          <units>log (pg/mL)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="-1.4" upper_limit="1.5"/>
                    <measurement group_id="O2" value="2.0" lower_limit="-1.6" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.17</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lansoprazole</title>
          <description>lansoprazole : 30 mg of lansoprazole twice daily for 6 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo comparator to lansoprazole 30 mg, twice daily for 6 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Questionnaires were not assessed as many of them were incomplete. Drop out occurred due to incomplete tissues Early termination: the total number of participants could not be enrolled in a timely manner..</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>kathryn peterson</name_or_title>
      <organization>university of utah</organization>
      <phone>8015817804</phone>
      <email>kathryn.peterson@hsc.utah.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

